TY  - JOUR

T1  - Venglustat, a novel glucosylceramide synthase inhibitor, in patients at risk of rapidly progressing ADPKD: primary results of a double-blind, placebo-controlled, phase 2/3 randomized clinical trial

JO  - American Journal of Kidney Diseases

PY  - 2022/12/16

AU  - Gansevoort RT

AU  - Hariri A

AU  - Minini P

AU  - Ahn C

AU  - Chapman AB

AU  - Horie S

AU  - Knebelmann B

AU  - Mrug M

AU  - Ong ACM

AU  - Pei YPC

AU  - Torres VE et al

ED  - 

DO  - DOI: 10.1053/j.ajkd.2022.10.016

PB  - Elsevier BV

Y2  - 2024/12/29

ER  -